InvAscent partially exits Symbiotec Pharmalab via IPO, pre-IPO share sales

Bitget2026/09/21 18:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

InvAscent advised Rosewood Investment on a partial exit from Symbiotec Pharmalab via pre-IPO share sales, followed by the IPO.
The partnership began with an INR 3.44 billion investment in December 2018; the fund retained a meaningful stake post-listing.
Symbiotec manufactures corticosteroid, steroid-hormone APIs; it has expanded into CDMO services and complex injectables during the holding period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invascent published the original content used to generate this news brief on September 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

InvAscent partially exits Symbiotec Pharmalab via IPO, pre-IPO share sales

You may also like

Crypto prices